Annovis Bio, Inc.: Annovis Bio to Present at the H.C. Wainwright Global Life Sciences Conference
Berwyn, Pennsylvania (Newsfile Corp. - March 9, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer s disease (AD), Parkinson s disease (PD) and other neurodegenerative diseases, today announced that Maria Maccecchini, Ph.D., Founder and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference. Annovis Bio s presentation will be available online beginning March 9, 2021 at 7:00 a.m. ET., and the presentation will be archived and available for replay for 90 days after the event.
The register and view the webcast, visit: https://journey.ct.events/view/f6675119-df47-4bf8-8553-6891b8fb3ee4
Cambridge Allergy Ltd: Camallergy Awarded £1.1 M Funding Under Innovate UK Biomedical Catalyst Award for Novel Peanut Allergy Treatment
-Company to provide corporate update at upcoming Global Life Sciences investor conference
Cambridge Allergy Ltd ( Camallergy or the Company ), a biopharmaceutical company dedicated to providing innovative, patient-centric treatments for life-threatening food allergies, today announced it has been awarded
£1.1M funding under the Innovate UK Biomedical Catalyst Award program administered by Innovate UK, the United Kingdom s research and innovation agency.
The
£1.1M in non-dilutive funding will be used to accelerate the Company s peanut allergy immunotherapy, CA002, for planned Phase 3 clinical trials. The project commences in the first quarter of 2021, and as part of the project s success, the Company intends to file its investigation new drug application with the FDA and submit a clinical trials application to the MHRA and EMA.
Berwyn, Pennsylvania (Newsfile Corp. - March 9, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced that Maria Maccecchini, Ph.D., Founder and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference. Annovis Bio's presentation will be available online beginning March 9, 2021 at 7:00 a.m. ET., and the presentation will be archived and available .
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved over 9% compound annual growth since formation, employs c.600 employees and is lis
About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility. The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.